Dr. Lal PathLabs Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2024-25, as required under Regulation 34 (2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The report includes general disclosures such as:
Corporate Identity Number (CIN): L74899DL1995PLC065388
Registered office address: Block E, Sector-18, Rohini, New Delhi-110085
Website: www.lalpathlabs.com
Paid-up capital: ₹ 83.59 crore divided into 8,35,91,735 Equity Shares of ₹ 10 each (As on March 31, 2025)
The company’s business activities primarily involve independent diagnostics/pathological laboratories, accounting for 100% of the turnover.
Operations:
The company has 298 locations nationally and 2 internationally (Nepal and Bangladesh).
Exports contribute 1.18% of the total turnover.
Employees (as on March 31, 2025):
Total employees: 1,830 (Male: 1,348, Female: 482)
Total workers: 3,478 (Male: 2,501, Female: 977)
CSR:
CSR is applicable as per section 135 of Companies Act, 2013.
Turnover: ₹ 2,351.6 Million (₹ 235.16 crore)
Net worth: ₹ 2,077.1 Million (₹ 207.71 crore)
Allocated ₹ 94.53 Million (₹ 9.45 crore) for Corporate Social Responsibility (CSR) activities during FY 2024-2025.
A section of the report details complaints/grievances on principles under the National Guidelines on Responsible Business Conduct (NGRBC), including those from communities, investors, shareholders, employees, customers and value chain partners.
The report identifies material responsible business conduct and sustainability issues, including workplace safety, employee training and development, employee benefits, energy management, fire safety and community development. Mitigation approaches for each risk are detailed.
The report includes management and process disclosures, detailing policies, governance, leadership and oversight related to business responsibility.
The report includes principle-wise performance disclosure and explains how the company is working towards:
Conducting business with integrity.
Providing goods and services in a sustainable and safe manner.
Promoting the well-being of employees.
Notes:
During the year under review, the Member(s) of Suburban Diagnostics (India) Private Limited, Wholly Owned Subsidiary (“Suburban”), in the Extra-ordinary General Meeting on February 06, 2025, accorded approval for voluntary liquidation of Suburban and expeditious consolidation of its business to the Company on a going concern subject to the compliance of applicable laws. Further, pursuant to the voluntary liquidation process, the Liquidator of Suburban, has distributed its entire business undertaking to the Company on a going concern basis on and with effect from close of business hours of March 18, 2025. In view of the same, data(s)/ information(s) of Suburban are also included under this report for the Financial Year 2024-25.